Peptide drugs are potential therapeutic agent used against several disease attributing to its features high activity, target specificity, low toxicity, and minimal non-specific or drug–drug interactions. The low physicochemical properties such as poor membrane permeability and low target specific action when administered orally demands for improved peptide drug. Glycosylation of peptides is a promising strategy to modulate the physicochemical properties of peptide drugs and for penetration of peptides across biological membranes. Glycosylation of a peptide can be of two type N-linked glycosylation or O-linked glycosylation. Glycosylation of peptide drug enhances bioactivity, selectivity and prolong half-life of therapeutic drug. Advantages offered by glycosylated peptide over conventional peptide drug are the key factor driving growth of the glycosylated peptide market. For instance, Amgen’s Aranesp is used for treatment of anemia associated with chronic renal failure (CRF), having 5 N-linked oligosaccharide chain, which has three fold longer half-life as compared to Epogen, a 3 N-linked oligosaccharide chain. Furthermore, product approvals, inorganic strategies by key players, and various application of glycosylated peptide are some of the factors driving growth of the glycosylated peptide market.

Glycosylated Peptide Market – Driver

New product launches by the key manufacturers are fueling growth of the glycosylated peptide market. For instance, in 2017, Pfizer Inc., received the U.S. Food and Drug Administration (FDA) approval for Ixifi (infliximab-qbtx), a chimeric human-murine monoclonal antibody, as a treatment for patients with rheumatoid arthritis, Crohn's disease, pediatric Crohn’s disease, ulcerative colitis, ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. Furthermore, in Feb 2017, CT-P10 received approval from the European Commission and in June 2017, it was approved by U.S. FDA. Furthermore, Sumsung Bioepis’s Infliximab biosimilar candidate SB2 got Ministry of Food and Drug Safety approval for Korea in 2016, European Commission approval for Europe in 2016, Therapeutic Goods Administration (TGA) approval for Australia in 2016, US FDA approval in 2017 and Health Canada (HC) approval of Canada in 2017. Moreover, company received European Commission (EC), Ministry of Food and Drug Safety (MFDS) and TGA approval for its Adalimumab biosimilar, SB5 in 2017 and 2018. However, challenges associated with the biosimilar product approval and stringent regulatory policies are restraining growth of the glycosylated peptide market.

Moreover, market players involved in the glycosylated peptide market are adopting strategies such as merger and acquisition for expanding geographical coverage or product portfolio. For instance, in 2014, Bachem AG, a peptide manufacturer and GlyTech Inc., a glycosylated drug developer, entered into co-promotional agreement for GlyTech’s glycosylation technology. The agreement will leverage Bachem by enhancing its sales and marketing resources and GlyTech to promote Bachem for manufacturing of its glycopeptides and glycoproteins. Moreover, in 2016, Teva Pharmaceutical Industries, Israel-based global pharmaceutical company, entered into commercial partnership with Celltrion Inc., a Korean based Biopharmaceutical company to commercialize two of Celltrion’s monoclonal antibody (mAb) biosimilar, CT-P10 (mAb biosimilar to Rituximab) candidates in the U.S. and Canada. The commercial partnership with Celltrion will enable Teva to strengthen its position in biosimilar products and Celltrion to expand its product to global market.

Increasing application of glycosylated peptide is expected to fuel growth of the glycosylated peptide market. For instance, in 2015, Sussex Research Laboratories Inc., a specialist in glycodesign and the synthesis of complex carbohydrates, announced successful clinical trials for Glycolastin, anti-aging glycopeptide cosmetic active. The in-vitro studies for comparing efficacy of Glycolastin against non-glycosylated peptide reported increased secretion of structural protein elastin, fibronectin, and collagens by fibroblast. Furthermore, company plans to commercialize Glycolastin, as a cosmetic active in topical anti-aging products.

Glycosylated Peptide Market - Regional Analysis

On the basis geography, the glycosylated peptide market is segmented into North America, Latin America, Europe, Middle East, Asia Pacific, and Africa. North America is expected to hold dominant position in glycosylated peptide market over the forecast period, owing to increasing FDA approved products in the region. Asia Pacific is expected to witness significant growth due to emerging market players and their market expansion strategies. For instance, in 2017, Amgen collaborated with Simcere Pharmaceutical Group for co-development and commercialization of its biosimiliar products along with its four undisclosed pipeline biosimilar products for the treatment of inflammation and oncology in China.

Glycosylated Peptide Market – Competitor

Major players operating in glycosylated peptide market include Pfizer Inc., Teva Pharmaceutical Industries Ltd., Bachem Holding AG, GlyTech, Inc., Sussex Research Laboratories Inc., Samsung Bioepis, and Celltrion Inc.

Glycosylated Peptide Market - Taxonomy

By Product